Affiliation:
1. N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia
2. Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia
Abstract
Bilateral nephroblastoma is rare and is about 5 % of the total number of patients. The modern strategy of treatment children with bilateral Wilms tumor requires a comprehensive approach. An important task is to preserve as much of the renal parenchyma as possible, which will be sufficient for normal kidney function and development of the child. However, in subtotal kidney damage organ-preserving treatment is not always possible. In this case, the only curative option is bilateral nephrectomy followed by continuous renal replacement therapy. To date, the literature describes isolated cases of adjuvant chemotherapy in children on peritoneal dialysis. The article presents a clinical case of specific therapy with topotecan for a child after bilateral nephrectomy, a carrier of peritoneal dialysis catheter on the background of progression of the underlying disease.
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Reference6 articles.
1. Kozlova V.M., Kazubskaya T.P., Sharoev T.A., Kirichenko O.P., Koshechkina N.A., Moiseenko E.I. Hereditary forms of Wilms tumor and their genetic counseling. Bulletin of the Federal State Budgetary Institution “N.N. Blokhin Russian Scientifi c Center” = Journal of N.N. Blokhin Russian Cancer Research Center 1998;9(2):6–12. (In Russ.)
2. Lugtenberg R.T., Cransberg K., Loos W.J., Wagner A., Alders M., van den Heuvel-Eibrink M.M. Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation. Cancer Chemother Pharmacol 2008;62(6):1039–44. doi: 10.1007/s00280-008-0694-x.
3. Ghanem M.A., van Steenbrugge G.J., Nijman R.J., van der Kwast T.H. Prognostic markers in nephroblastoma (Wilms’ tumor). Urology 2005;65(6):1047–54. doi: 10.1016/j.urology.2004.12.005.
4. Little S.E., Hanks S.P., King-Underwood L., Jones C., Rapley E.A., Rahman N., Pritchard-Jones K. Frequency and heritability of WT1 mutations in nonsyndromic Wilms’ tumor patients: a UK Children’s Cancer Study Group Study. J Clin Oncol 2004;22(20):4140–6. doi: 10.1200/JCO.2004.02.136.
5. Soff er S.Z., Kim E., Moore J.T., Huang J., Yokoi A., Manley C., O’Toole K., Middlesworth W., Stolar C., Yamashiro D., Kandel J. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg 2001;36(12):1781–4. doi: 10.1053/jpsu.2001.28823.